Sign Out
Switching Patients to Different Type of Insulin: Transferring a patient to another type of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (rapid acting insulin, intermediate acting insulin, long acting insulin etc), species (animal, Insulin human analog) and/or method of manufacturer (recombinant versus animal source insulin) may result in the need for a change in dose. Patients switching to Winsulin-N/Winsulin-30/70/Winsulin-R may require a change in dosage from that used with their usual insulin.
Laboratory Tests: As with all insulins, the therapeutic response to human insulin should be monitored by periodic blood glucose tests. Periodic measurement of glycosylated hemoglobin is recommended for the monitoring of long term glycemic control.
Renal Impairment: The requirements for insulin may be reduced in patients with renal impairment.
Hepatic Impairment: Although impaired hepatic function does not affect the absorption or disposition of isophane insulin human suspension-NPH/Winsulin-30/70/Insulin human Regular, careful glucose monitoring and dose adjustments of insulin may be necessary.
Effects on the ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operation machinery). Patients should therefore be advised to avoid hypoglycemia during driving. This is particularly significant in particularly who have reduced awareness of the warning signs of hypoglycemia or have frequent episodes of hypoglycemia.
